DiaSorin launches new parvovirus B19 test

DiaSorin has launched a new molecular diagnostic test for the detection of parvovirus B19 on plasma and serum samples in international territories outside North America.

The IAM Parvo test is the third test released for the Liaison IAM platform and has been designed to be highly sensitive, allowing it to provide confirmation data in a rapid and authoritative manner.

Because it can offer a prompt diagnosis of infection, clinicians can adequately monitor the evolution of the condition and make appropriate care referrals, which can be particularly important for immunocompromised patients or those with sickle cell anaemia.

Carlo Rosa, chief executive officer of DiaSorin, said the new product launch "reaffirms our plan to develop a strong and structured molecular business through high-quality and reliable specialty products".

The firm is also currently developing new molecular assays for infectious diseases and onco-haematology that it plans to commercialise later this year and in 2014.

Based in Italy, DiaSorin has been producing and marketing reagent kits for in vitro diagnostics worldwide for more than 40 years.